1-10 of 10
Fangfang Lv
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song
Journal: Blood
Blood (2023) 142 (Supplement 1): 1720.
https://doi.org/10.1182/blood-2023-186788
Published: 2023
Journal Articles

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael L. Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6501–6503.
https://doi.org/10.1182/blood-2022-162135
Published: 2022
Journal Articles

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Yizhen Liu, Qunling Zhang, Fangfang Lv, Xiaojian Liu, Dongmei Ji, Zuguang Xia, Jia Jin, Rong TAO, Wenhao Zhang, Xiaoqiu Li, Shengjian Zhang, Jiachen Wang, Xiaonan Hong, Junning Cao
Journal: Blood
Blood (2022) 140 (Supplement 1): 6627–6628.
https://doi.org/10.1182/blood-2022-158657
Published: 2022
Journal Articles

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Guang-Liang Chen, Pin Guo, Shiyu Jiang, Juan J. Gu, Qunling Zhang, Yizhen Liu, Junning Cao, Xiaonan Hong, Rong TAO, Fangfang Lv
Journal: Blood
Blood (2022) 140 (Supplement 1): 3790–3791.
https://doi.org/10.1182/blood-2022-156877
Published: 2022
Journal Articles

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Clinical Trials & Observations
Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Jane Huang, William Novotny, Pil Kim, Yiling Yu, Binghao Wu, Jun Zhu
Journal: Blood
Blood (2022) 139 (21): 3148–3158.
https://doi.org/10.1182/blood.2021014162
Published: 2022
Includes: Supplemental data
Journal Articles

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Barrett H Childs, Yuankai Shi, Pier Luigi Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 3538.
https://doi.org/10.1182/blood-2021-150873
Published: 2021
Journal Articles

Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Yuqin Song, MD PhD, Quanli Gao, MD, Lei Fan, MD PhD, Dehui Zou, MD, Huilai Zhang, MD PhD, Jianfeng Zhou, MD PhD, Wei Li, MD, Haiyan Yang, MD PhD, Ting Liu, MD PhD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Dan Wang, PhD, Pei Zhang, PhD, Tengfei Liu, PhD, Yun Zhang, PhD, Zhirong Shen, PhD, Lei Wang, PhD, Liudi Yang, MD, Haiyi Guo, MD, Jun Zhu, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17.
https://doi.org/10.1182/blood-2020-136696
Published: 2020
Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5233.
https://doi.org/10.1182/blood-2019-128878
Published: 2019
Journal Articles

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Yuqin Song, MD PhD, Quanli Gao, MD, Huilai Zhang, PhD, Lei Fan, MD PhD, Jianfeng Zhou, PhD, Dehui Zou, MD, Wei Li, MD, Haiyan Yang, PhD, Ting Liu, MD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Yu Yang, MD, Haiyi Guo, MD, Liudi Yang, MD, Rebecca Elstrom, MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 682.
https://doi.org/10.1182/blood-2018-99-117848
Published: 2018
Journal Articles

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Yuqin Song, MD PhD, Keshu Zhou, MD, Dehui Zou, MD, Jianfeng Zhou, PhD, Jianda Hu, PhD, Haiyan Yang, PhD, Huilai Zhang, PhD, Jie Ji, MD, Wei Xu, MD PhD, Jie Jin, MD PhD, Fangfang Lv, MD, Ru Feng, MD, Sujun Gao, PhD, Daobin Zhou, MD, Haiyi Guo, MD, Aihua Wang, PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Muhtar Osman, PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 148.
https://doi.org/10.1182/blood-2018-99-117956
Published: 2018